Elsevier

Schizophrenia Research

Volume 159, Issue 1, October 2014, Pages 205-210
Schizophrenia Research

Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapies,☆☆

https://doi.org/10.1016/j.schres.2014.07.018Get rights and content

Abstract

Objective

Cognition is affected by circadian rhythms over the course of a day. Circadian rhythms in cognitive functioning are driven by a variety of both endogenous and exogenous factors. Patients with schizophrenia are known to have disturbed circadian rhythms that can affect their cognitive functioning. We examined the impact of time of day on cognitive test scores from subjects participating in clinical trials of potential pro-cognitive therapies for schizophrenia and then explored how this diurnal variation affected signal detection.

Method

Baseline data from 8 separate schizophrenia clinical trials using the MATRICS Consensus Cognitive Battery (MCCB) were aggregated (Total N = 2032). The MCCB assessments were divided into five 2-hour time intervals based on the start-time of the assessments (varying from 8:00 am to 5:59 pm) and then analyzed for differences by time interval. Next, data from two Phase 2 schizophrenia clinical trials of potential pro-cognitive therapies were analyzed to explore the impact of this diurnal variation on placebo separation.

Results

Time of day exerted a significant effect on baseline composite MCCB scores (p = .002). Follow-up comparisons revealed significant differences among multiple temporal epochs. In both Phase 2 clinical trials, subjects whose cognitive functioning was assessed at consistent times of day between their baseline and endpoint visits showed a more robust treatment response as compared to subjects assessed at inconsistent times of day.

Conclusion

Cognitive functioning ebbs and flows over the course of the day. Maintaining consistency in the time of day of cognitive test administrations between visits can help to reduce the noise introduced by circadian rhythms, thereby enhancing signal detection in clinical trials of potential pro-cognitive therapies.

Introduction

Over one hundred years ago, while performing groundbreaking research into human learning, memory, and forgetting, Hermann Ebbinghaus made the following observation about the impact of time of day on cognitive functioning:

In the later hours of the day mental vigor and receptivity are less. The series learned in the morning and then relearned at a later hour, aside from other influences, require more work for relearning than they would if the relearning were done at a time of mental vigor equal to that of the original learning.

Ebbinghaus (1885)

From this simple observation regarding the impact of time of day on the learning of nonsense syllables, a wealth of studies has now established that circadian rhythms in cognitive functioning are pervasive and affect a wide variety of cognitive processes, including attention (Valdez et al., 2005), vigilance (Buysse et al., 2005, Hoffman et al., 2005), phonological and visual working memory (Ramirez et al., 2006), declarative memory (Johnson et al., 1992), procedural memory (Cajochen et al., 2004), dual-task processing (Van Eekelen and Kerkhof, 2003), inhibition (May and Hasher, 1998), cognitive flexibility (May et al., 1999), and a wide variety of executive functions (Blatter and Cajochen, 2007, Schmidt et al., 2007). These variations in functioning also tend to follow a pattern over the course of a day and are not simply random noise. A typical pattern of diurnal variation in cognitive functioning reflects that performance often peaks mid-morning and then gradually decreases over the course of the day (Blatter and Cajochen, 2007), sometimes with an exacerbation of poor performance in the mid-afternoon (Wertz et al., 2006, Wright et al., 2012). Inter-individual differences in circadian rhythms, called chronotypes, have also been identified. For example, differences in morning versus evening chronotypes have been found to vary by age, with the performance of young adults sometimes improving over the day, while it deteriorates among older adults, especially among executive and memory domains (Hasher et al., 1999, Schmidt et al., 2007).

Circadian rhythms in cognitive functioning are driven by a variety of both endogenous and exogenous factors. Endogenous factors affecting diurnal variation in cognitive performance include sleep pressure, which increases with time spent awake and is reflected in increases in fatigue and sleepiness. Another endogenous factor is the circadian time process (i.e., the circadian ‘pacemaker’), which is a nearly 24-hour oscillatory variation in sleep propensity. This circadian pacemaker affects brain arousal through projections from the master circadian clock, located in the hypothalamic suprachiasmatic nuclei, and via clock gene oscillations in a variety of brain tissues (Wright et al., 2012). A variety of exogenous factors can also impact diurnal variation in cognitive performance, including food intake and its resulting changes in blood glucose, caffeine intake, motivation, and lighting, to name just a few (Wertz et al., 2006, Schmidt et al., 2007).

Patients suffering from a variety of psychiatric disorders have been found to have disturbed circadian rhythms, including major depressive disorder (Courtet and Olié, 2012), bipolar disorder (Ciarleglio et al., 2011), and schizophrenia (Wulff et al., 2012). In regard to schizophrenia specifically, sleep disturbances are known to adversely affect cognition (Manoach and Stickgold, 2009). Clinically, sleep disturbance may predict the onset of psychosis (Ruhrmann et al., 2010) and psychotic relapse following therapy with antipsychotics (Chemerinski et al., 2002). Some researchers have postulated that the common comorbidity between sleep disturbances and schizophrenia may reflect shared biological diatheses underlying both conditions (Pritchett et al., 2012).

Recently, several small studies have specifically examined circadian rhythm abnormalities among patients with schizophrenia. Wulff et al. (2012) conducted a 6-week study of 20 outpatients with schizophrenia and 21 healthy controls and examined the magnitude of circadian disruptions by collecting sleep-wake data using actigraphy along with weekly 48-hour profiles of a urinary metabolite of melatonin. A markedly delayed and/or free-running sleep-wake cycle was seen among 50% of the patients with schizophrenia, implying a lack of synchrony between the body's internal rhythm and the external day-night cycle. No evidence was found that the dose of antipsychotic medication was related to any of the circadian abnormalities, which is consistent with the broader literature suggesting that sleep disturbances in schizophrenia are not merely side effects of antipsychotic therapy (Pritchett et al., 2012). Bromundt et al. (2011) examined the connection between circadian abnormalities and cognitive functioning among 14 patients with schizophrenia using a combination of continuous wrist actigraphy, salivary samples of melatonin secretions, and repeated assessments of patients' neuropsychological functioning and clinical symptoms over 3 weeks. Despite the small sample size, the relative amplitude of sleep-wake cycles significantly predicted performance on all of the cognitive measures, and was superior to all other predictors of cognitive performance, including age, positive and negative symptom scale scores on the Positive and Negative Syndrome Scale (PANSS), and sleep efficiency. Lastly, D'Reaux et al. (2000) examined the impact of time of day on cognitive functioning between a group of 14 patients with schizophrenia and contrasted them to a group of 14 normal controls. They found that time of day of testing did have a significant effect on cognitive performance for both healthy controls and patients. In particular, the patients with schizophrenia had both poorer performance and a distinct pattern of time of day effects in terms of their cognitive functioning as compared with the normal controls, with patients having better afternoon cognitive performance on measures of visual memory and motor measures as compared to their morning performance.

Numerous clinical trials focused on cognitive impairments in schizophrenia have been conducted focusing on a wide variety of potential mechanisms of action for pro-cognitive activity, from nicotinic alpha-7 receptor agonism to 5-HT2A antagonism. However, to date the majority of these trials have been negative. It is not well understood at present the extent to which these trials failed because of inadequate or misfocused psychopharmacology, methodological issues that may have precluded signal detection, or a combination of both or other factors.

Based on the literature review above, we hypothesized that patients with schizophrenia would exhibit a circadian rhythm in their cognitive functioning. Moreover, we hypothesized that taking into account this diurnal variation in cognitive functioning would serve to enhance signal detection in clinical trials of potential pro-cognitive therapies by eliminating an important source of error variance from the data. To test these hypotheses, we first examined the impact of time of day on patients' baseline performance on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) (Nuechterlein et al., 2008) across 8 large Phase 2, US-based, schizophrenia clinical trials. Next, we compared placebo separation between groups of subjects with consistent versus inconsistent timing of cognitive battery administrations by analyzing their change from baseline scores. This enabled us to determine whether subjects tested at consistent times of day, thus reducing diurnal variation, would show enhanced placebo separation as compared to subjects tested at inconsistent times of day. For these analyses, we examined data from two Phase 2 potential pro-cognitive schizophrenia clinical trials, one of an adjunctive alpha-7 nicotinic acetylcholine receptor agonist, and the other of a broad-spectrum γ-aminobutyric acid-enhanced antipsychotic agent.

Section snippets

Methods

First, MCCB baseline assessments were aggregated across 2032 subjects from US sites in 8 different schizophrenia clinical trials for the diurnal variation analyses. These 8 clinical trials were chosen because data from them were available for these analyses. Consistent with the construction and use of the MCCB in clinical trials, we focused our analyses on the composite score, which is derived from the ten subtests and resulting 7 domain scores, that comprise the battery (Nuechterlein et al.,

Results

Baseline MCCB administrations from 8 Phase 2, US-based, schizophrenia clinical trials (N = 1915) were first examined to assess the impact of time of day on subjects' cognitive performance. The mean age of subjects was 42.9 (SD = 9.88), and 32% were women. The mean MCCB composite score across all subjects at baseline was 25.6 (SD = 12.00). LS means of the baseline composite score were compared over the five 2-hour intervals between 8:00 am and 5:59 pm and ranged from 25.3 (SE = 0.57) in the 10:00–11:59 AM

Discussion

Aggregated data across 8 large clinical trials support the hypothesis that circadian rhythms affect cognitive functioning among patients with schizophrenia. Time of day exerted a significant effect among the baseline MCCB composite scores, with a maximum variation of 3.7 T-score points (approximately 1/3rd of standard deviation) occurring between five 2-hour intervals over the course of the day. The pattern of variation was broadly aligned with those often observed in circadian research into

Role of funding source

Financial support for this research was provided by NeuroCog Trials, Inc., (Durham, NC).

Contributors

Michael Hufford, Ph.D. designed this analysis and managed the literature searches and analyses and wrote the first draft of the manuscript. Vicki Davis, Dr.P.H. undertook the statistical analyses. Dana Hilt, Nancy Dgetluck, Yona Geffen, Antony Loebel, George Haig, Luca Santarelli all helped to provide data for the project and were involved in the analytic planning. Richard Keefe helped with the analysis of the results and also contributed to the manuscript's development. All authors contributed

Conflict of interest

Michael Hufford is a co-founder and employee of e-Nicotine Technology. Vicki Davis is an employee of NeuroCog Trials. Dana Hilt, M.D. and Nancy Dgetluck, Ph.D. are both full-time employees of EnVivo Pharmaceuticals. Yona Geffen, Ph.D. was a full-time employee at BioLineRx and is currently employed by Avraham Pharmaceuticals. Antony Loebel, M.D. is a full-time employee of Sunovion Pharmaceuticals. George Haig, Pharm.D., M.B.A. is a full-time employee of Abbvie Pharmaceuticals. Luca Santarelli,

Acknowledgments

The authors would like to thank Dana Hilt, M.D., Maria Gawryl, Ph.D., Nancy Dgetluck, Ph.D. and Alon Rappaport, M.D. for their support of these analyses, and Aaron Stern and Noah Stern for their support of data management. Dana Hilt, Maria Gawryl, and Nancy Dgetluck are employees of EnVivo Pharmaceuticals (Watertown, MA) and Alon Rappaport is an employee of BioLineRx (Jerusalem, Israel). Aaron Stern and Noah Stern are employees of NeuroCog Trials (Durham, NC).

References (31)

  • H. Ebbinghaus

    Memory: A Contribution to Experimental Psychology

    (1885)
  • Y. Geffen et al.

    BL-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study

    J. Clin. Psychiatry

    (2012)
  • L. Hasher et al.

    Timing, instructions, and inhibitory control: some missing factors in the age and memory debate

    Gerontology

    (1999)
  • J.M. Hoffman et al.

    Time of day and sleep inertia effects on cognitive performance and sleepiness during chronic sleep restriction. Dutch Society for Sleep

    Wake Res.

    (2005)
  • M.P. Johnson et al.

    Short-term memory, alertness and performance: a reappraisal of their relationship to body temperature

    J. Sleep Res.

    (1992)
  • Cited by (8)

    • Effects of an extrinsic motivator on the evaluation of cognitive and daily living functions in patients with schizophrenia

      2020, Schizophrenia Research
      Citation Excerpt :

      Clinical symptoms such as depression and negative symptoms are known to impair cognitive and daily living functions (Berman et al., 1997; Ventura et al., 2009). Intraday variations might also exist, even with stable clinical symptoms; therefore, repeated examinations should be performed at the same time of day (Hufford et al., 2014). To minimize the effects of medication, such as anticholinergic effects, on the test results, the type and dose of medication should be controlled between the test and retest (Kim et al., 2019).

    • Inflammation in individuals with schizophrenia – Implications for neurocognition and daily function

      2018, Brain, Behavior, and Immunity
      Citation Excerpt :

      Neurocognition was assessed using the MATRICS Consensus Cognitive Battery (MCCB; Nuechterlein et al., 2008) with the MCCB composite score serving as a primary variable of interest (adjusted for age, gender). All MCCB tests were administered on weekdays between 9 and 11am to minimize the influence of diurnal variation on neurocognition (Hufford et al., 2014). Daily functioning was assessed using the Specific Level of Functioning Scale (SLOF; Schneider & Struening, 1983) via informants, typically first-degree relatives residing with the participant.

    • A method of real listing stratified psychiatry for multidimensional signatures and trajectories on big data platform & cloud computing

      2020, Proceedings - 2020 5th International Conference on Mechanical, Control and Computer Engineering, ICMCCE 2020
    View all citing articles on Scopus

    These results have previously been presented at the 2012 autumn conference of the International Society for CNS Clinical Trials and Methodology (Marina del Rey, CA).

    ☆☆

    Clinical trials registrations: ClinicalTrials.gov identifiers NCT00567710, NCT00968851, NCT01077700, NCT01095562, NCT01192880, NCT01192906, NCT01192867, NCT00604760, NCT00641745.

    View full text